medigraphic.com
ISSN 2683-1678 (Print)
Órgano Oficial de la Sociedad
Latinoamericana de lnfectología Pediátrica.
Órgano de la Asociación Mexicana de
Infectología Pediátrica, A.C.
Órgano difusor de la Sociedad Española
de lnfectología

2019, Number 4

<< Back Next >>

Rev Latin Infect Pediatr 2019; 32 (4)

Impact of rotavirus vaccination in Mexico and Latin America: realities and new perspectives

Xochihua DL, Angulo CE, Herrera BIF, Luévanos VA, Macías PM, Mascareñas SA, Moreno ES, Ortiz IFJ, Ortiz CB, Rodríguez BE, González SN

Language: Spanish
References: 66
Page: 145-156
PDF size: 316.16 Kb.


ABSTRACT

Rotavirus infections are considered the principal cause of morbidity and mortality in infants under two years, adults over 65 and immunocompromised hosts. The objective of this consensus was to analyze and discuss the vaccination impact on the burden of rotavirus disease in Mexico and Latin America. Methods: Using an academic consensus model, we analyzed and discussed the available scientific literature related to the rotavirus epidemiological changes and several controversial topics. We followed the recommendations of the «Guidelines for planning consensus» and the recommendations and useful criteria for the critical reading of the European initiative «AGREE» (Appraisal of Guidelines for Research & Evaluation). We integrate mixed and representative teams conformed by pediatrics infection disease and clinical microbiologists with molecular techniques training, and conducted a selective search to obtain the used studies and manuscripts for this review. The identification of the articles was carried out using the following keywords: rotavirus, rotavirus vaccine, epidemiology, exchangeable vaccine, among others. The chosen keywords were among the period from January 2013 to May 2018. The selected articles were written in English and Spanish and were obtained using the PubMed, Google Scholar, EMBASE and Cochrane search engines. Results: We raised a total of seven relevant issues. The representative teams analyzed the concerns and built recommendations based on the critical review of the selected articles.


REFERENCES

  1. Ferrario C, Califano G, Durán P A et al. Lineamientos para la elaboración de consensos. Arch Argent Pediatr. 2012; 110 (2): 163-167. doi: org/10.5546/aap.2012.163.

  2. The AGREE Collaboration. Appraisal of Guidelines for Research & Evaluation (AGREE) Instrument. Disponible en: https://www.agreetrust.org/resource-centre/the-originalagree-instrument/

  3. Birtwhistle R, Pottie K, Shaw E et al. Canadian task force on preventive health care: ¡we’re back! Can Fam Physician. 2012; 58 (1): 13-15.

  4. GBD Diarrhoeal Diseases Collaborators. Estimates of global, regional, and national morbidity, mortality, and aetiologies of diarrhoeal diseases: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Infect Dis. 2017; 17 (9): 909-948.

  5. Fischer WCL, Perin J, Aryee MJ, Boschi-Pinto C, Black RE. Diarrhea incidence in low- and middle-income countries in 1990 and 2010: a systematic review. BMC Public Health. 2012; 12: 220.

  6. Fischer Walker CL, Aryee MJ, Boschi-Pinto C, Black RE. Estimating diarrhea mortality among young children in low- and middle-income countries. PLoS ONE. 2012; 7 (1): e29151.

  7. Tucker AW, Haddix AC, Bresee JS, Holman RC, Parashar UD, Glass RI. Cost-effectiveness analysis of a rotavirus immunization program for the United States. JAMA. 1998; 279 (17): 1371-1376.

  8. INEGI. Características de las defunciones registradas en México durante 2017. Comunicado de Prensa Número 525/18, 31 de octubre del 1028, página 13.

  9. Blacklow NR, Greenberg HB. Viral gastroenteritis. N Engl J Med. 1991; 325: 252-264.

  10. Glass RI, Parashar UD, Estes MK. Norovirus gastroenteritis. N Engl J Med. 2009; 361: 1776-1785.

  11. Bosch A, Pint RM, Guix S. Human astroviruses. Clin Microbiol Rev. 2014; 27: 1048-1074.

  12. Oka T, Wang Q, Katayama K, Saif LJ. Comprehensive review of human sapoviruses. Clin Microbiol Rev. 2015; 28: 32-53.

  13. Troeger C, Khalil IA, Rao PC et al. Rotavirus vaccination and the global burden of rotavirus diarrhea among children younger than 5 years. JAMA Pediatr. 2018; 172 (10): 958-965.

  14. Boletín Epidemiológico-Dirección General de Epidemiología de SS Número 30 | Volumen 36 | Semana 30 | Del 21 al 27 julio del 2019.

  15. Parashar UD, Alexander JP, Glass RI. Prevention of rotavirus gastroenteritis among infants and children: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recommendations and Reports. 2006; 55 (RR-12): 1-13.

  16. Linhares AC, Velázquez FR, Pérez-Schael I et al. Human rotavirus vaccine study group. efficacy and safety of an oral live attenuated human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in Latin American infants: a randomised, double-blind, placebo-controlled phase III study. Lancet. 2008; 371 (9619): 1181-1189.

  17. Tate JE, Burton AH, Boschi-Pinto C, Steele AD, Duque J, Parashar UD; WHO-coordinated Global Rotavirus Surveillance Network. 2008 estimate of worldwide rotavirus-associated mortality in children younger than 5 years before the introduction of universal rotavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect Dis. 2012; 12 (2): 136-141.

  18. Lanata CF, Fischer-Walker CL, Olascoaga AC, Torres CX, Aryee MJ, Black RE; Child Health Epidemiology Reference Group of the World Health Organization and UNICEF. Global causes of diarrheal disease mortality in children <5 years of age: a systematic review. PLoS One. 2013; 8 (9): e72788.

  19. Velazquez FR, Matson DO, Calva JJ et al. Rotavirus infections in infants as protection against subsequent infections. N Engl J Med. 1996; 335: 1022-1028.

  20. Gladstone BP, Ramani S, Mukhopadhya I et al. Protective effect of natural rotavirus infection in an Indian birth cohort. N Engl J Med. 2011; 365: 337-346.

  21. Hu L, Crawford SE, Czako R et al. Cell attachment protein VP8* of a human rotavirus specifically interacts with A-type histo-blood group antigen. Nature. 2012; 485: 256-259.

  22. Nordgren J, Sharma S, Bucardo F et al. Both Lewis and secretor status mediate susceptibility to rotavirus infections in a rotavirus genotype-dependent manner. Clin Infect Dis. 2014; 59: 1567-1573.

  23. Böhm R, Fleming FE, Maggioni A et al. Revisiting the role of histo-blood group antigens in rotavirus host-cell invasion. Nat Commun. 2015; 6: 5907.

  24. Greenberg HB, Estes MK. Rotaviruses: from pathogenesis to vaccination. Gastroenterology. 2009; 136: 1939-1951.

  25. Franco MA, Greenberg HB. Challenges for rotavirus vaccines. Virology. 2001; 281: 153-155.

  26. McNeal MM, Basu M, Bean JA et al. Identification of an immunodominant CD4+ T cell epitope in the VP6 protein of rotavirus following intranasal immunization of BALB/c mice. Virology 2007; 363: 410-18.

  27. Kuklin NA, Rott L, Feng N et al. Protective intestinal anti-rotavirus B cell immunity is dependent on alpha 4 beta 7 integrin expression but does not require IgA antibody production. J Immunol. 2001; 166: 1894-1902.

  28. Corthesy B, Benureau Y, Perrier C et al. Rotavirus anti-VP6 secretory immunoglobulin A contributes to protection via intracellular neutralization but not via immune exclusion. J Virol. 2006; 80: 10692-10699.

  29. Ball JM, Tian P, Zeng CQ, Morris AP, Estes MK. Age-dependent diarrhea induced by a rotaviral nonstructural glycoprotein. Science. 1996; 272: 101-104.

  30. Choi NW, Estes MK, Langridge WH. Oral immunization with a shiga toxin B subunit: rotavirus NSP4(90) fusion protein protects mice against gastroenteritis. Vaccine. 2005; 23: 5168-5176.

  31. Adams MJ, Lefkowitz EJ, King AMQ et al. Changes to taxonomy and the International Code of Virus Classification and Nomenclature ratified by the International Committee on Taxonomy of Viruses (2017). Arch Virol. 2017; 162 (8): 2505-2538.

  32. Schoondermark‐van de Ven E, Van Ranst M, de Bruin W et al. Rabbit colony infected with a bovine‐like G6P[11] rotavirus strain. Vet Microbiol. 2013; 166 (1‐2):154‐164.

  33. Trojnar E, Sachsenröder J, Twardziok S. Identification of an avian group A rotavirus containing a novel VP4 gene with a close relationship to those of mammalian rotaviruses. J Gen Virol. 2013; 94: 136-142.

  34. Li K, Lin XD, Huang KY et al. Identification of novel and diverse rotaviruses in rodents and insectivores, and evidence of cross-species transmission into humans. Virology. 2016; 494: 168-177.

  35. Matthijnssens J, Ciarlet M, McDonald SM et al. Uniformity of rotavirus strain nomenclature proposed by the Rotavirus Classification Working Group (RCWG). Arch Virol. 2011; 156 (8): 1397-1413.

  36. Rotavirus Classification Working Group (RCWG) [Internet]. Newly assigend genotypes. 2017. Available in: https://rega.kuleuven.be/cev/viralmetagenomics/virus-classification/rcwg.2017

  37. Matthijnssens J, Van Ranst M. Genotype constellation and evolution of group A rotaviruses infecting humans. Curr Opin Virol. 2012; 2 (4): 426-433.

  38. ROTA Council. Global introduction status. [Acceso: 21 de agosto de 2019] Available in: http://rotacouncil.org/vaccine-introduction/global-introduction-status/

  39. Aliabadi N, Tate JE, Haynes AK, Parashar UD. Sustained decrease in laboratory detection of rotavirus after implementation of routine vaccination-United States, 2000-2014. Morb Mortal Wkly Rep. 2015; 64: 337-342.

  40. Patel MM, Glass R, Desai R, Tate JE, Parashar UD. Fulfilling the promise of rotavirus vaccines: how far have we come since licensure? Lancet Infect Dis. 2012; 12: 561-570.

  41. Gastañaduy PA, Curns AT, Parashar UD, Lopman BA. Gastroenteritis hospitalizations in older children and adults in the United States before and after implementation of infant rotavirus vaccination. J Am Med Assoc. 2013; 310: 851-853.

  42. Pollard SL, Malpica-Llanos T, Friberg IK et al. Estimating the herd immunity effect of rotavirus vaccine. Vaccine. 2015; 33 (32): 3795-3800.

  43. Glass RI, Parashar U, Patel M, Gentsch J, Jiang B. Rotavirus vaccines: successes and challenges. J Infect. 2014; 68 Suppl 1: S9-S18.

  44. do Carmo GM, Yen C, Cortes J et al. Decline in diarrhea mortality and admissions after routine childhood rotavirus immunization in Brazil: a time-series analysis. PLoS Med. 2011; 8: e1001024.

  45. Richardson V, Hernández-Pichardo J, Quintanar-Solares M et al. Effect of rotavirus vaccination on death from childhood diarrhea in Mexico. N Engl J Med. 2010; 362: 299-305.

  46. Armah GE, Sow SO, Breiman RF et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trial. Lancet. 2010; 376: 606-614.

  47. Soares-Weiser K, Bergman H, Henschke N, Pitan F, Cunliffe N. Vaccines for preventing rotavirus diarrhoea: vaccines in use. Cochrane Database Syst Rev. 2019; 3: CD008521.

  48. Tate JE, Burton AH, Boschi-Pinto C et al. Global, Regional, and National Estimates of Rotavirus Mortality in Children <5 Years of Age, 2000-2013. Clin Infect Dis. 2016; 62 Suppl 2: S96-S105.

  49. Lanzieri TM, Linhares AC, Costa I et al. Impact of rotavirus vaccination on childhood deaths from diarrhea in Brazil. Int J Infect Dis. 2011; 15: e206-e210.

  50. Bayard V, DeAntonio R, Contreras R et al. Impact of rotavirus vaccination on childhood gastroenteritis-related mortality and hospital discharges in Panama. Int J Infect Dis. 2012; 16: e94-e98.

  51. Sánchez-Uribe E, Esparza-Aguilar M, Parashar UD, Richardson V. Sustained reduction of childhood diarrhea-related mortality and hospitalizations in Mexico after rotavirus vaccine universalization. Clin Infect Dis. 2016; 62 Suppl 2: S133-S139. doi: 10.1093/cid/civ1205.

  52. Luna-Casas G, Juliao P, Carreño-Manjarrez R et al. Vaccine coverage and compliance in Mexico with the two-dose and three-dose rotavirus vaccines. Hum Vaccin Immunother. 2019; 15 (6): 1251-1259.

  53. Krishnarajah G, Davis EJ, Fan Y, Standaert BA, Buikema AR. Rotavirus vaccine series completion and adherence to vaccination schedules among infants in managed care in the United States. Vaccine. 2012; 30: 3717-3722. doi: 10.1016/j.vaccine.2011.12.077.

  54. Panozzo CA, Becker-Dreps S, Pate V et al. Patterns of rotavirus vaccine uptake and use in privately-insured US infants, 2006-2010. PLoS One. 2013; 8 (9): e73825. doi: 10.1371/journal.pone.0073825. eCollection 2013.

  55. Burnett E, Parashar U, Tate J. Rotavirus vaccines: effectiveness, safety, and future directions. Paediatr Drugs. 2018; 20: 223-233.

  56. Kirkwood CD, Steele AD. Rotavirus vaccines in China: improvement still required. JAMA Netw Open. 2018; 1 (4): e181579.

  57. Riveros X. Overview of characteristics of RV vaccines licensed and/or in clinical evaluation phase World Health Organization. 2017. https://www.who.int/immunization/research/meetings_workshops/3_RV_vaccines_RX_oct17.pdf

  58. Le T, Nguyen V, Nguyen T et al. Advances in research on Rotavin-M1. VJST. 2017; 59 (1): 43-48. Available in: http://vietnamscience.vn/index.php/VJSTE/article/view/25

  59. Pêra FF, Mutepfa DL, Khan AM et al. Engineering and expression of a human rotavirus candidate vaccine in Nicotiana benthamiana. Virol J. 2015; 12: 205.

  60. Li T, Lin H, Zhang Y et al. Improved characteristics and protective efficacy in an animal model of E. coli-derived recombinant double-layered rotavirus virus-like particles. Vaccine. 2014; 32 (17): 1921-1931. doi: 10.1016/j.vaccine.2014.01.093.

  61. Wen X, Cao D, Jones RW, Li J, Szu S, Hoshino Y. Construction and characterization of human rotavirus recombinant VP8* subunit parenteral vaccine candidates. Vaccine. 2012; 30 (43): 6121-6126. doi: 10.1016/j.vaccine.2012.07.078.

  62. Li Y, Xue M, Yu L et al. Expression and characterization of a novel truncated rotavirus VP4 for the development of a recombinant rotavirus vaccine. Vaccine. 2018; 36 (16): 2086-2092. doi: 10.1016/j.vaccine.2018.03.011.

  63. Xue M, Yu L, Jia L, Li Y, Zeng Y, Li T et al. Immunogenicity and protective efficacy of rotavirus VP8* fused to cholera toxin B subunit in a mouse model. Hum Vaccin Immunother. 2016; 12 (11): 2959-2968.

  64. Groome MJ, Koen A, Fix A et al. Safety and immunogenicity of a parenteral P2-VP8-P[8] subunit rotavirus vaccine in toddlers and infants in South Africa: a randomised, double-blind, placebo-controlled trial. Lancet Infect Dis. 2017; 17 (8): 843-853.

  65. Cortes-Penfield NW, Ramani S, Estes MK, Atmar RL. Prospects and challenges in the development of a norovirus vaccine. Clin Ther. 2017; 39 (8): 1537-1549.

  66. Kanai Y, Komoto S, Kawagishi T et al. Entirely plasmid-based reverse genetics system for rotaviruses. Proc Natl Acad Sci U S A. 2017; 114 (9): 2349-2354.




2020     |     www.medigraphic.com